NYSE: HUM · Healthcare Plans
Humana (HUM) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Humana (HUM) at $411.63 a share. The stock last closed at $461.25, which puts the model's fair value 10.8% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Humana Inc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $397.68 to $411.63 (+3.5%). Analysts raised their next-twelve-month EBITDA estimates: part of the move.
What the model makes of itThe price of $461.25 is 10.8% above it: Fairly valued, on a medium evidence grade.
What's nextNext report on 10 Feb 2027. Options prices imply a move of about 12% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give HUM?
The calibrated range for HUM over 63 trading days is $400.23 to $535.39. It sits around the last close, and its width comes from the volatility that HUM's own options imply (43% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $330.99 to $507.12. In 36% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Humana Inc. is a prominent health and well-being enterprise that operates across the United States through its subsidiary companies. Its three main segments are Retail, Group and Specialty, and Healthcare Services.
Faircurve's model put the fair value of Humana at $411.63 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $397.68, so the fair value moved +3.5%. In the model's own words, analysts raised their next-twelve-month EBITDA estimates, which is part of the move. The calibrated range over 63 trading days is $400.23 to $535.39. It is built around the price from the volatility the stock's own options imply, and calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon, across 8,038 past valuations. The evidence grade is Medium. The grade covers input completeness, the number and agreement of comparable companies, and the width of the range of outcomes. It does not say whether the fair value is right.
Humana scores 46 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Growth quality is the strongest factor at 71, with trailing revenue growth of 10.1% against a peer median of 11.8%. Profitability is the weakest at 23, with ROIC of 6.1% against a peer median of 10.6%. The model compares Humana with Cigna Corporation, Centene Corp., Elevance Health Inc., CVS Health Corp., Molina Healthcare, Inc., UnitedHealth Group Incorporated and Progyny, Inc.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does HUM report earnings, and how has the stock reacted?
Humana's next earnings report is scheduled for 10 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 5.4% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. HUM's 30 day implied volatility works out to about 12.4% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across HUM's last 8 reports, ignoring direction, was 2.9%.
What the options market has priced for a month's move in HUM
How does HUM score on business quality?
Humana's overall quality score is 46 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 23 | 6.1%ROIC | 10.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 47 | 0.60xFCF / net income | 0.95x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 71 | 10.1%Revenue growth, trailing | 11.8% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 49 | 0.3%Net buybacks / market value | 2.8% |
| Balance sheetNet debt to EBITDA and interest coverage. | 53 | 1.72xNet debt / EBITDA | 2.18x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 54 | 1.0 ptsEBITDA margin downside volatility, 5y | 0.8 pts |
How does HUM compare with similar companies?
The companies in healthcare plans closest to Humana in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| CI Cigna Corporation | $300.16 | $384.76 | +28.2% | Undervalued |
| CNC Centene Corp. | $74.77 | $86.49 | +15.7% | Undervalued |
| ELV Elevance Health Inc. | $446.28 | $454.75 | +1.9% | Fairly valued |
| CVS CVS Health Corp. | $88.59 | $89.93 | +1.5% | Fairly valued |
| MOH Molina Healthcare, Inc. | $233.09 | $227.64 | -2.3% | Fairly valued |
| UNH UnitedHealth Group Incorporated | $412.02 | $405.70 | -1.5% | Fairly valued |
| PGNY Progyny, Inc. | $37.15 | $34.78 | -6.4% | Fairly valued |
What the comparable companies' multiples alone would give for HUM, the peer-implied price, is $296.94 a share on this run. The fair value weighs that against the company's own multiple.
Humana at a glance
Humana Inc., a prominent health and well-being enterprise, operates across the United States through its various subsidiary companies. Its operational structure is divided into three main segments: Retail, Group and Specialty, and Healthcare Services.
- Market value
- $54.0B
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Revenue expected, next twelve months
- $172.6B
- Consensus revenue growth, next fiscal year
- +25.6%
- Analysts with estimates
- 14
- Beta to the US market
- 0.50
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. HUM was not among them.
How the fair value is worked out: the model prices Humana on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for HUM was $397.68. As of 14 Nov 2026 it is $411.63, a change of +3.5%. Analysts raised their next-twelve-month EBITDA estimates: part of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Humana's valuation
Is Humana stock undervalued or overvalued?
On Faircurve's model, HUM reads as Fairly valued as of 14 Nov 2026. The model's fair value is $411.63 a share against a last close of $461.25, a gap of -10.8%.
What is HUM's fair value?
$411.63 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $330.99 to $507.12.
What price range does the model give HUM?
$400.23 to $535.39 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Humana report earnings next?
The next report is scheduled for 10 Feb 2027. Companies can move their dates.
How much has HUM moved on past earnings reports?
Across its last 8 reports the median two session move was 2.9%, ignoring direction. The largest was -10.9% around the report of 5 Nov 2025.
How confident is the model in this valuation?
The model's evidence grade for HUM is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on HUM
The model holds no idea open on HUM today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on HUM with their outcomes. A free account is enough.